HD-OPM Archive
Topics › Statins

STAREE: atorvastatin cut major CV events 30% in adults 70+ with no rise in dementia

Louis Nervegna · Nov 01, 2026 · ♥ 5 reactions · 5 comments · original Facebook post
StatinsBrain health & dementiaHeart attack, stroke & procedures
AI summary & key facts

A quoted summary of the STAREE trial in NEJM: 9,971 adults aged 70 or older without cardiovascular disease, diabetes or dementia were randomized to atorvastatin 40 mg or placebo for a median 5.9 years. Atorvastatin cut major cardiovascular events 30% and MI and revascularization 43% each, with no significant increase in dementia or all-cause mortality and equal serious adverse events.

Statins & Dementia - The STAREE trial

Quoted:

Statins and Dementia? Well let’s have a look see in a new primary prevention trial of older adults that looked at Dementia risk in addition to cardiac risk.

The new STAREE trial, published in the New England Journal of Medicine, randomized 9,971 adults age 70+ with no known cardiovascular disease, diabetes, or dementia to atorvastatin 40 mg or placebo and followed them for a median of 5.9 years.

This was an investigator-initiated study with no commercial or industry involvement.

The results:

You’re allowed to dislike statins.

You’re allowed to discuss their limitations and adverse effects.

But you don’t get to invent your own data.

And the claim that statins cause dementia and don’t prevent heart disease is simply not an evidence-based position.

📚 Reference:
Zoungas S, et al. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. N Engl J Med. 2026;395:1259-1272. DOI: 10.1056/NEJMoa2607314.

#statinsdementiaHD #statinsHD #stareeHD #atorvastatinHD #dementiaHD #alzheimersHD

Research cited

← newer: Two randomized trials of statins as Alzheimer's treatment weolder: Observational, randomized and genetic evidence all argue aga →